CASI Pharmaceuticals (CASI) Competitors

CASI Pharmaceuticals (NASDAQ:CASI) and Elutia (NASDAQ:ELUT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, media sentiment, analyst recommendations, community ranking, dividends, earnings, institutional ownership and profitability.

Do insiders and institutionals have more ownership in CASI or ELUT?

22.2% of CASI Pharmaceuticals shares are owned by institutional investors. Comparatively, 74.0% of Elutia shares are owned by institutional investors. 21.2% of CASI Pharmaceuticals shares are owned by insiders. Comparatively, 27.6% of Elutia shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Does the media prefer CASI or ELUT?

In the previous week, Elutia had 1 more articles in the media than CASI Pharmaceuticals. MarketBeat recorded 3 mentions for Elutia and 2 mentions for CASI Pharmaceuticals. CASI Pharmaceuticals' average media sentiment score of 0.93 beat Elutia's score of 0.81 indicating that CASI Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CASI Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Elutia	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has stronger earnings & valuation, CASI or ELUT?

CASI Pharmaceuticals has higher revenue and earnings than Elutia. Elutia is trading at a lower price-to-earnings ratio than CASI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CASI Pharmaceuticals	$28.54M	0.85	-$26.94M	-$2.57	-0.77
Elutia	$24.38M	3.82	-$37.66M	-$2.47	-0.92

Is CASI or ELUT more profitable?

CASI Pharmaceuticals has a net margin of -143.18% compared to Elutia's net margin of -218.72%. Elutia's return on equity of 0.00% beat CASI Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CASI Pharmaceuticals	-143.18%	-181.52%	-45.72%
Elutia	-218.72%	N/A	-142.61%

Do analysts recommend CASI or ELUT?

CASI Pharmaceuticals currently has a consensus price target of $4.00, suggesting a potential upside of 102.43%. Elutia has a consensus price target of $9.00, suggesting a potential upside of 294.05%. Given Elutia's higher possible upside, analysts plainly believe Elutia is more favorable than CASI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CASI Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Elutia	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has more volatility and risk, CASI or ELUT?

CASI Pharmaceuticals has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500. Comparatively, Elutia has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500.

Does the MarketBeat Community prefer CASI or ELUT?

CASI Pharmaceuticals received 190 more outperform votes than Elutia when rated by MarketBeat users. However, 100.00% of users gave Elutia an outperform vote while only 48.91% of users gave CASI Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
CASI Pharmaceuticals	Outperform Votes 201 48.91%	Underperform Votes 210 51.09%
Elutia	Outperform Votes 11 100.00%	Underperform Votes No Votes

Summary

Elutia beats CASI Pharmaceuticals on 11 of the 17 factors compared between the two stocks.